Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease.
about
Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry DiseaseImproving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methodsEnzyme replacement therapy for Fabry disease: some answers but more questionsIdentification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests.Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.Pharmacological chaperone therapy for Fabry diseaseThe Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense MutationsUsing CRISPR/Cas9-Mediated GLA Gene Knockout as an In Vitro Drug Screening Model for Fabry Disease.Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.Functional analysis of variant lysosomal acid glycosidases of Anderson-Fabry and Pompe disease in a human embryonic kidney epithelial cell line (HEK 293 T).Synthesis of lipophilic 1-deoxygalactonojirimycin derivatives as D-galactosidase inhibitors.Taming molecular flexibility to tackle rare diseases.Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns.
P2860
Q28553021-7F6C0F48-25F1-488E-8603-B14B62A7D113Q33541145-2B5261AD-87BE-4856-B764-907A90283CB5Q34703815-263A20B9-377C-4832-8F0E-AF3B35D3B97AQ35007910-E53C78F4-8038-40A2-88DC-168E4FD8878FQ35550530-2D8E10F2-C16C-4031-BE80-3DE25523E834Q35587768-ABBB7EC1-0E31-4F8B-94C8-609CA5EE4E54Q35755438-5A7767CC-63E3-41EC-8D03-356618B75C6AQ36213022-A97C118D-45F2-4696-A5D7-0A12C71AF8E3Q37534808-EC838F23-367E-4274-9FDB-9850D9DC526DQ38797648-B9369F3B-3EAD-4E4D-8F4E-D009A393A23AQ39463106-E3D787A0-7F64-4015-A62B-63BE4A0F39A7Q40683720-61305345-C1C3-4D7F-8BA5-FBFC1CECA364Q40960071-4C68FB38-00F3-4632-A043-E0E23A560FC9Q53469658-E0C0546E-6346-4EAB-80AA-097A58356F29
P2860
Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Effects of a chemical chaperon ...... n patients with Fabry disease.
@en
Effects of a chemical chaperon ...... n patients with Fabry disease.
@nl
type
label
Effects of a chemical chaperon ...... n patients with Fabry disease.
@en
Effects of a chemical chaperon ...... n patients with Fabry disease.
@nl
prefLabel
Effects of a chemical chaperon ...... n patients with Fabry disease.
@en
Effects of a chemical chaperon ...... n patients with Fabry disease.
@nl
P2093
P2860
P1476
Effects of a chemical chaperon ...... n patients with Fabry disease.
@en
P2093
Gu Hwan Kim
Han Wook Yoo
Jin Joo Lee
Jung Min Ko
Jung Young Park
Sung Su Kim
P2860
P2888
P356
10.3858/EMM.2009.41.1.001
P577
2009-01-01T00:00:00Z
P5875
P6179
1050699203